相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Medicine, General & Internal
S. F. Lumley et al.
Summary: In a longitudinal study of seropositive and seronegative health care workers undergoing asymptomatic and symptomatic SARS-CoV-2 testing, the presence of anti-spike or anti-nucleocapsid IgG antibodies was associated with a substantially reduced risk of SARS-CoV-2 reinfection in the ensuing 6 months.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Noa Dagan et al.
Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Joseph E. Ebinger et al.
Summary: Virus-specific antibody levels after a single dose of the BNT162b2 vaccine in individuals previously infected with SARS-CoV-2 are similar to levels after two doses of the vaccine in infection-naive individuals. Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose.
Article
Medicine, General & Internal
He S. Yang et al.
Summary: The study found that there are distinct viral-specific antibody response profiles in different age groups with children showing higher levels of antibody response. Therefore, age-targeted strategies for disease screening, management, and vaccine development may be necessary.
Article
Medicine, General & Internal
Elizabeth Fraley et al.
Summary: This study characterized humoral immune responses during vaccination with the BNT162b2 vaccine in individuals with or without prior history of natural SARS-CoV-2 infection, demonstrating differences in antibody levels and epitope specificity between the two groups. The findings support the consideration of prior infection history as a guide for future vaccination strategies and provide valuable insights for vaccine development.
Article
Public, Environmental & Occupational Health
Andrea Lombardi et al.
Summary: The study found that vaccination with BNT162b2 can enhance immunity acquired through infection, especially for individuals infected more than 6 months before vaccination.
JOURNAL OF INFECTION AND PUBLIC HEALTH
(2021)
Article
Immunology
Julien Favresse et al.
Summary: The study aimed to assess the antibody response in healthcare professionals who had received the BNT162b2 mRNA COVID-19 vaccine, finding a decline in antibody levels at 3 months post-vaccination but maintaining a robust immune response.
EMERGING MICROBES & INFECTIONS
(2021)
Article
Immunology
Li Guo et al.
CLINICAL INFECTIOUS DISEASES
(2020)
Article
Biochemistry & Molecular Biology
Quan-Xin Long et al.
Article
Medicine, General & Internal
Fernando P. Polack et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
Article
Immunology
Nisreen M. A. Okba et al.
EMERGING INFECTIOUS DISEASES
(2020)
